V2 hotspot optimized MVA vaccine expressing stabilized HIV-1 Clade C envelope Gp140 delays acquisition of heterologous Clade C Tier 2 challenges in Mamu-A*01 negative Rhesus Macaques.

Front Immunol · 2022 · PMC9353326 · PMID 35935987

Europe PMC DOI

hedged sentences

0.1000

closest p · 2.0× alpha

0.1000

boldest claim

The sentences

showed a trendp=0.1so close (0.05 < p ≤ 0.1)

The MVA-150 group also showed a trend (p=0.1) for delay in acquisition of SHIV infection with an estimated vaccine efficacy of 57%.

also in 53,322 other papers

did not reach statistical significanceno p-value reported

The protection in the Mamu-A*01- animals of DM-150 (57% per exposure) was comparable to the protection in the DM-UFO group but did not reach statistical significance probably due to relatively small group sizes (n=6/group).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.